Related Experiment Video
Updated: May 20, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Overdose of pegfilgrastim: case report
Gisela Riu1, Anna Estefanell, Meritxell Nomdedeu
1Pharmacy Service, Hospital Clínic de Barcelona, c/Villarroel, 170, Escalera 8 sótano, 08036 Barcelona, Spain. gisbcn@hotmail.com
A patient with T-cell lymphoma received an accidental pegfilgrastim overdose during chemotherapy. Close monitoring revealed no adverse effects, suggesting this is key for managing pegfilgrastim overdose.
Area of Science:
- Oncology
- Pharmacology
Background:
- Pegfilgrastim is a granulocyte-colony stimulating factor (G-CSF) used in single doses post-chemotherapy.
- It supports neutrophil recovery, reducing infection risk in cancer patients.
Observation:
- A 59-year-old male with Stage III-B CD4+ peripheral T-cell lymphoma received CHOP-14 chemotherapy.
- An error resulted in four consecutive daily doses of pegfilgrastim instead of the intended single dose.
- The patient was hospitalized for observation following the overdose.
Findings:
- The patient exhibited no significant symptoms or laboratory abnormalities during the three days post-pegfilgrastim administration.
- Discharge occurred without immediate complications related to the overdose.
Implications:
- This case highlights the importance of vigilant patient monitoring in instances of pegfilgrastim overdose.
- Available literature supports close observation as the primary management strategy for accidental pegfilgrastim overdosage.
Related Concept Videos
Drug Toxicity: Allergic Reactions
Drug toxicity: Idiosyncratic Reactions
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Drug Toxicity: Risk factors
Drug Toxicity: Overview
Pharmaceutical Poisoning: Potential Scenarios